Related Experiment Video
Updated: Aug 7, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Pathogenesis of thrombocytopenia in cyanotic congenital heart disease
Michael C Lill1, Joseph K Perloff, John S Child
1The Ahmanson/UCLA Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Insights
Twenty-five percent of patients with cyanotic congenital heart disease (CCHD) have low platelet counts due to reduced platelet production. This may stem from whole megakaryocytes bypassing the lungs, impacting platelet formation in CCHD patients.
Area of Science:
- Cardiology
- Hematology
- Pathophysiology
Background:
- A notable percentage of patients with cyanotic congenital heart disease (CCHD) experience thrombocytopenia.
- The underlying causes and frequency of thrombocytopenia in CCHD remain incompletely understood.
Purpose of the Study:
- To investigate the prevalence and pathogenesis of thrombocytopenia in patients with CCHD.
- To explore the relationship between platelet production, megakaryocyte mass, and platelet activation in CCHD.
Main Methods:
- Assessed platelet counts, reticulated platelet counts, thrombopoietin levels, and markers of disseminated intravascular coagulation and platelet activation in 105 CCHD patients.
- Compared findings to 20 healthy controls.
Main Results:
- Twenty-five percent (26/105) of CCHD patients exhibited thrombocytopenia (platelet count <100x10(9)/L), all diagnosed with Eisenmenger syndrome.
- Reduced platelet production was identified as the cause, despite normal megakaryocyte mass and minimal platelet activation.
- Hypothesized that right-to-left shunts lead to megakaryocytes bypassing pulmonary maturation, reducing platelet counts.
Conclusions:
- Thrombocytopenia in CCHD is linked to decreased platelet production, not increased destruction or consumption.
- Platelet counts in CCHD may exist on a spectrum, from low-normal to overtly thrombocytopenic.
- The proposed mechanism involves altered megakaryocyte trafficking due to intracardiac shunting.
Abstract:
Although a significant minority of patients with cyanotic congenital heart disease (CCHD) are thrombocytopenic, the pathogenesis and prevalence have not been established. This study was designed to address these 2 issues. We included 105 patients with CCHD (60 men and 45 women; aged 21 to 54 years). Systemic arterial oxygen saturations were 69% to 78%. Hematocrits were 62% to 74% with normal iron indexes. In 26 of 105 patients (25%), platelet counts were <100x10(9)/L. The diagnosis was Eisenmenger syndrome in all 26 patients with thrombocytopenia. Platelet production was determined by flow cytometric reticulated platelet counts. Megakaryocyte mass was determined indirectly by thrombopoietin levels. Disseminated intravascular coagulation was based on prothrombin time, activated partial thromboplastin time, and D-dimers. Platelet activation was determined by levels of platelet factor 4 and beta thromboglobulin. Reference ranges were derived from 20 normal acyanotic controls. A reduction in absolute reticulated platelet counts implied decreased platelet production (p<0.001). Normal thrombopoietin levels implied normal megakaryocyte mass. Normal prothrombin time, activated partial thromboplastin time, and D-dimers excluded disseminated intravascular coagulation. Normal platelet factor 4 and beta thromboglobulin indicated absent or minimal platelet activation. Twenty-five percent of the patients with CCHD were thrombocytopenic because platelet production was decreased despite normal megakaryocyte mass. We hypothesized that right-to-left shunts deliver whole megakaryocytes into the system arterial circulation, bypassing the lungs where megakaryocytic cytoplasm is fragmented into platelets, thus reducing platelet production. In conclusion, platelet counts in CCHD appear to represent a continuum beginning with low normal counts and ending with thrombocytopenia.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

